NCT03936907View on ClinicalTrials.gov

Comparison of Safety, Tolerability and Pharmacokinetics of Medical Grade Cannabis (MGC) Orally Disintegrating Tablets With Buccal Sativex®, in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 15, 2019

Primary Completion Date

July 18, 2019

Study Completion Date

July 18, 2019

Conditions

Healthy Subjects

Interventions

DRUG

OWCP Orally Disintegrating Tablet

Medical Grade Cannabis - Orally Disintegrating Tablet (MGC-ODT) containing 5 mg THC and 5 mg CBD

DRUG

Sativex

Sativex® Oromucosal Spray

Trial Locations (1)

6423906

Tel Aviv Sourasky Medical Center, Tel Aviv

All Listed Sponsors

lead

One World Cannabis Ltd.

INDUSTRY

NCT03936907 - Comparison of Safety, Tolerability and Pharmacokinetics of Medical Grade Cannabis (MGC) Orally Disintegrating Tablets With Buccal Sativex®, in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter